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Check et ul. ' reported in 1990, three women with very elevated, early first trimester CA125 concentrations, who subsequently spontaneously aborted in the late first or early second trimester, and in whom the products of conception showed chromosomal abnormalities (Trisomy 12 and 13, 45X, Trisomy 21). Check et al. ' concluded that a high maternal serum CAl25 concentration might be predictive of an abnormal karyotype.
Following this initial observation I have considered the possibility that CA125, if truly an indicator of abnormal karyotype, may still be elevated in viable second trimester pregnancies. Furthermore, if this was the case, then it might prove to be a useful screening test for Down's syndrome (Trisomy 21) or as an adjunct to other serological marker^.^,^ In order to test the hypothesis, 25 maternal serum samples from Down's syndrome pregnancies were identified from stores of abnormal samples, along with five unaffected control cases for each Down's case. The controls were matched for gestational age (k 3 days), maternal age ( k 6 months) and a length of storage (k 1 month).
A further series of samples, covering the gestational age range 16-20 weeks, were chosen at random from our pool of normal singleton pregnancies. An additional series of samples was identified in which the pregnancy ended in intra uterine death (10 cases) or spontaneous abortion (10 cases).
All samples were analysed for CA125 using a solid phase two site monoclonal immunoradiometric assay (ELSA-CA125, CIS (UK) Ltd, High Wycombe, UK) according to the manufacturer's protocol. Since there is no International Standard for CA125, the results were expressed in arbitrary units (U/mL) as determined by the kit manufacturer. The samples were spread evenly over five different assay batches and the between assay precision was found to be 3.8% coefficient of variation at 119 U/mL and 8.2% at 20 U/mL.
To allow for possible variation in CA125 levels with gestational age, all values were expressed as multiples of the median (MOM) value for unaffected pregnancies of the same gestational age. Table 1 summarizes the data showing the variation of CA125 with gestational age. The data showed only minor variation; only the change from 16 to 17 weeks being possibly statistically significant ( 0 . 0 5 > P > 0 . 0 2 ) using t tests of significance. The combined median for all the normal data (n = 231) was 19.4 U/mL. There was no correlation of CA125 with maternal age (r=0.00199). CA125 concentrations in the Down's pregnancy samples are shown in Fig. 1 , along with the multiple of the median at the various gestational ages. C A 125 concentrations in Down's pregnancies showed no statistically significant difference from those in the unaffected population, with the median MOM for the Down's group being 0.945. The population distribution data and the summary statistics (after log transformation of the data) are shown in Tables 2 and 3 . A possible explanation for the raised concentrations found in the three cases described by Check el ul.,I is most likely t o relate to impending ('r) and I0 cases of spontaneous abortion (+) .
fetal death, since in my 10 cases of intrauterine death and 10 cases of spontaneous abortion, CA125 levels were greater than 2 MOM in 40% of both cases (Fig. 2) . One of the major causes of death in the first trimester of fetal life is chromosomal abnormality and of the three cases cited by Check et a/.' trisomy 12 and 13 is incompatible with life, in trisomy 45X only about 10% survive to term, whilst in trisomy 21 some 40-50'70 survive to term. From the data in this present study it can be concluded that CA125 is not a second trimester marker for Down's syndrome and is therefore unlikely to have any role to play in the second trimester prenatal screening for this abnormality.
